Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
CLS Therapeutics
New York, New York, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
CLS Therapeutics’ lead asset CLS-014 is a novel adeno-associated vector encoding a hyperactive DNase I enzyme for degrading extracellular DNA, targeting advanced/metastatic pancreatic adenocarcinoma. The company received FDA Orphan Drug Designation in 2022 for CLS-014 in pancreatic cancer. Early stage research suggests potential utility in other solid tumor indications, including a licensed DNase platform for 'DNase-Armored' CAR T cell therapy in collaboration with Xenetic Biosciences and VolitionRx.
- Therapeutic areas
- Oncology
- Modalities
- Gene therapyRecombinant proteinAdeno-associated viral vectorCell therapy
- Industry
- Biotech
02
Partnerships
Xenetic BiosciencesVolitionRx Limited
Beyond the preview
Go deeper on CLS Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CLS Therapeutics.